US5817461A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for diagnosis of hyperhomocysteinemia
Assignee: Hamilton General Hospital
•
Filing: 1996-01-03
•
Granted: 1998-10-06
•
Expires: 2016-01-03
Abstract
Abstract A method for diagnosing hyperhomocysteinemia by molecular genetic means is disclosed.
Inventors
- 👤 Richard C. Austin
- 👤 Jack Hirsh
- 👤 Jeffrey I. Weitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 06:05
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6809; A; A61; A61P; A61P9/00; A61P9/10; C12Q1/6876; C12Q1/6883; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; C12Q2600/00; C12Q2600/158; G01N2800/00; G01N2800/22; G01N2800/226
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
71 words
A method for diagnosing an individual having hyperhomocysteinemia and/or a predisposition to developing premature atherosclerosis, comprising: determining an expression level of dhc-1 mRNA in a cellular sample obtained from the individual, whereby an expression level of the dhc-1 mRNA at least two-fold higher than normal levels indicates the likely presence of hyperhomocysteinemia and/or a predisposition to developing premature atherosclerosis, and wherein the dhc-1 mRNA is substantially identical to SEQ ID NO:5.
Claim 2
Independent Claim
71 words
A method for diagnosing an individual having hyperhomocysteinemia and/or a predisposition to developing premature atherosclerosis, comprising: determining an expression level of dhc-1 mRNA in a cellular sample obtained from the individual, whereby an expression level of the dhc-1 mRNA at least two-fold higher than normal levels indicates the likely presence of hyperhomocysteinemia and/or a predisposition to developing premature atherosclerosis, and wherein the dhc-1 mRNA is substantially identical to SEQ ID NO:5.
Claim 3
Dependent Claim
46 words
The method of claim 1, wherein the determination of the expression level of the dhc-1 mRNA is performed by nucleic acid hybridization with a probe polynucleotide comprising a sequence of at least 25 nucleotides which is substantially identical to a complementary sequence of SEQ ID NO:5.
Claim 4
Dependent Claim
49 words
The method of claim 1, wherein the determination of the expression level of the dhc-1 mRNA is performed by polynucleotide amplification with a primer or primer set comprising a sequence of at least 25 nucleotides which is substantially identical to a corresponding or complementary sequence of SEQ ID NO:5.
Claim 5
Dependent Claim
50 words
The method of claim 1, wherein the expression level is determined by nucleic acid hybridization, polynucleotide amplification, or other means of quantitating relative abundance of an mRNA species, and the quantitation result determined for the dhc-1 mRNA is standardized to a quantitation result in the same sample for GAPDH mRNA.
Claim 6
Dependent Claim
8 words
A purified polynucleotide fragment comprising SEQ ID NO:5.
Claim 7
Dependent Claim
8 words
A purified polynucleotide fragment comprising SEQ ID NO:5.
References Cited (Backward Citations)
US5565323A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-10-05 | 2002-04-06 | 2002-10-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-10-05 | 2006-04-06 | 2006-10-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-10-05 | 2010-04-06 | 2010-10-06 | $7700.00 | Window Closed / Lapsed |